For citations:
Karateev A.E., Polishchuk E.Yu., Potapova A.S., Matyanova E.V., Semashko A.S., Bobkova А.O., Filatova E.S., Amirjanova V.N., Glukhova S.I., Zotkin E.G., Lila A.M. The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients. Rheumatology Science and Practice. 2022;60(2):149-156. (In Russ.) https://doi.org/10.47360/1995-4484-2022-149-156
Email this article 